| Revenue growth | Standalone FY26 revenue grew 31% YoY to ₹162cr. |
|---|---|
| Margins | Standalone EBITDA margin at 20%; Consolidated FY26 margin at 12%. |
| Order book | Secured long-term CDMO contracts strengthening revenue visibility. |
| Demand visibility | Strong visibility from 67 dossiers under development for export growth. |
Growth
FY26 standalone revenue grew 31% to ₹162cr; consolidated revenue reached ₹381cr.
Outlook
Capex of ₹111cr for capacity expansion; new Adelaide facility on track for Q4FY27 completion.
Risks
Economic volatility in international markets and competition in the generic formulation space.
Earnings Call filed with NSE, NSE: SAIPARENT. Summary written with AI assistance from the document.
Sai Parenterals Ltd: key numbers
- Share price
- ₹503.95
- Market cap
- ₹2,226 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 107.2×Sector 50.4×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 4.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Earnings Call Transcript: Key Takeaways
Management is pivoting to acquisitions after regulatory shifts blocked organic expansion in Hyderabad. While revenue growth appears strong due to the Numed consolidation, margins were hurt by high logistics costs in Australia.
Sai Parenterals Investor Presentation: Key Takeaways
Sai Parenterals is transitioning from a domestic-focused player to an export-driven CDMO/branded generic platform through major acquisitions and capacity expansion. Q1 FY27 presentation focuses on IPO proceeds variation and global accreditation strategy.
Sai Parenterals Q1 FY27 Results: Net Profit ₹7.9 Cr, Up 464.3% YoY
Sai Parenterals Ltd reported revenue from operations of ₹178.7 Cr (+435.0% YoY) and net profit of ₹7.9 Cr (+464.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹7.9 Cr · +464.3% YoY
Sai Parenterals Earnings Call: Key Takeaways
Sai Parenterals reports transformational FY26 following the Noumed acquisition. Focus shifts from asset building to monetization through vertical integration and expanding the CDMO export business.
Sai Parenterals Q3 FY26 Results: Net Loss of ₹6.7 Cr
Sai Parenterals Ltd reported revenue from operations of ₹96.2 Cr and a net loss of ₹6.7 Cr for Q3 FY26.
- Key figure
- Net loss ₹6.7 Cr